We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

51 hedge funds and large institutions have $162M invested in Dianthus Therapeutics in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 5

19% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 16

6% more funds holding

Funds holding: 48 → 51 (+3)

0.13% more ownership

Funds ownership: 2.44% → 2.57% (+0.13%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

11% less capital invested

Capital invested by funds: $182M → $162M (-$19.9M)

Holders
51
Holders Change
+3
Holders Change %
+6.25%
% of All Funds
1.17%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
12
Reduced
5
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CC
Casdin Capital
New York
+$2.83M
2
OM
Opaleye Management
Massachusetts
+$2.3M
3
Fidelity International
Fidelity International
Bermuda
+$1.71M
4
BlackRock
BlackRock
New York
+$942K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$914K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$1.51M
2
Citadel Advisors
Citadel Advisors
Florida
-$1.17M
3
Goldman Sachs
Goldman Sachs
New York
-$1.02M
4
Alkeon Capital Management
Alkeon Capital Management
New York
-$918K
5
Norges Bank
Norges Bank
Norway
-$893K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
51
Millennium Management
New York
– -$1.51M -6,984 Closed
Citadel Advisors
52
Citadel Advisors
Florida
– -$1.17M -5,425 Closed
Goldman Sachs
53
Goldman Sachs
New York
– -$1.02M -4,719 Closed
Alkeon Capital Management
54
Alkeon Capital Management
New York
– -$918K -4,250 Closed
UOC
55
UBS O'Connor
Illinois
– -$810K -3,750 Closed
DIM
56
DC Investments Management
Virginia
– -$558K -2,583 Closed
HI
57
HBK Investments
Texas
– -$338K -1,563 Closed
Blackstone Inc
58
Blackstone Inc
New York
– -$236K -1,094 Closed
CIBC Private Wealth Group
59
CIBC Private Wealth Group
Georgia
– -$215K -994 Closed
MWNA
60
Marshall Wace North America
New York
– -$135K -625 Closed
SSA
61
Schonfeld Strategic Advisors
New York
– -$135K -625 Closed
Tudor Investment Corp
62
Tudor Investment Corp
Connecticut
– -$135K -625 Closed
Point72 Asset Management
63
Point72 Asset Management
Connecticut
– -$109K -506 Closed
PHK
64
Point72 Hong Kong
Hong Kong
– -$109K -506 Closed
CSS
65
Cubist Systematic Strategies
Connecticut
– -$10K -47 Closed
CCA
66
Catalyst Capital Advisors
New York
– -$5K -24 Closed
Bank of Montreal
67
Bank of Montreal
Ontario, Canada
– +$421 +2 New
1 2
3

DNTH Hedge Fund Activity: Q3 2018 in Review

51 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2018, worth a combined $162M — down 11% from $182M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new DNTH positions and 16 closed out — a net gain of 3 holders — while 12 added to existing stakes and 5 trimmed.

The largest buyer was Casdin Capital, adding an estimated $2.83M. The largest seller was Millennium Management, exiting entirely with an estimated $1.51M sold.

  • 51 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2018, up from 48 in Q2 2018.
  • Funds reported $162M of Dianthus Therapeutics stock for Q3 2018, down 11% quarter-over-quarter.
  • 19 funds opened new Dianthus Therapeutics positions in Q3 2018 and 16 closed out, a net change of +3 holders.
  • The largest Dianthus Therapeutics buyer in Q3 2018 was Casdin Capital, an estimated $2.83M added.
  • The largest Dianthus Therapeutics seller in Q3 2018 was Millennium Management, an estimated $1.51M sold.

Based on aggregated 13F filings for Q3 2018.